Details for New Drug Application (NDA): 022525
✉ Email this page to a colleague
The generic ingredient in NAMENDA XR is memantine hydrochloride. There are twenty-eight drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the memantine hydrochloride profile page.
Summary for 022525
Tradename: | NAMENDA XR |
Applicant: | Abbvie |
Ingredient: | memantine hydrochloride |
Patents: | 1 |
Formulation / Manufacturing: | see details |
Pharmacology for NDA: 022525
Mechanism of Action | NMDA Receptor Antagonists |
Medical Subject Heading (MeSH) Categories for 022525
Suppliers and Packaging for NDA: 022525
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
NAMENDA XR | memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022525 | NDA | Allergan, Inc. | 0456-3414 | 0456-3414-33 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0456-3414-33) |
NAMENDA XR | memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022525 | NDA | Allergan, Inc. | 0456-3421 | 0456-3421-33 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0456-3421-33) |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 7MG | ||||
Approval Date: | Jun 21, 2010 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Sep 24, 2029 | Product Flag? | Substance Flag? | Delist Request? | Y |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 14MG | ||||
Approval Date: | Jun 21, 2010 | TE: | AB | RLD: | Yes | ||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Sep 24, 2029 | Product Flag? | Substance Flag? | Delist Request? | Y |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 21MG | ||||
Approval Date: | Jun 21, 2010 | TE: | AB | RLD: | Yes | ||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Sep 24, 2029 | Product Flag? | Substance Flag? | Delist Request? | Y |
Expired US Patents for NDA 022525
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | NAMENDA XR | memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022525-001 | Jun 21, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbvie | NAMENDA XR | memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022525-004 | Jun 21, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbvie | NAMENDA XR | memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022525-002 | Jun 21, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbvie | NAMENDA XR | memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022525-003 | Jun 21, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription